Evidence map›Paper›PMID 39654854›Full record

ArticleMass spectrometry (Tokyo, Japan)2024

Fragmentation Considerations Using Amidoamine Oxide Homologs.

Atsushi Yamamoto, Naoji Tokai, Rie Kakehashi, Daisuke Saigusa

Abstract read
In one paragraph

Article in Mass spectrometry (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Atsushi YamamotoFaculty of Environment, Tottori University of Environmental Studies, 1-1-1 Wakabadaikita, Tottori, Tottori 689-1111, Japan.
Naoji TokaiOsaka Research Institute of Industrial Science and Technology, 1-6-50 Morinomiya, Joto-ku, Osaka 536-8553, Japan.
Rie KakehashiOsaka Research Institute of Industrial Science and Technology, 1-6-50 Morinomiya, Joto-ku, Osaka 536-8553, Japan.
Daisuke SaigusaFaculty of Pharmaceutical Sciences, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the mass spectrometric analysis of 10 novel amidoamine oxide compounds, which are innovative hydrogelators for polar solvents. This research aims to identify characteristic fragment patterns for these amide compounds using high-resolution mass spectrometry. Methanol solutions of the compounds were analyzed in positive and negative ion modes, and MS1 and MS2 spectra at 6 collision energy levels were obtained via electrospray ionization and hybrid tandem mass spectrometry. The importance of low-intensity peaks in structure elucidation was emphasized because low-intensity fragments could provide crucial structural information, especially for compounds with similar structures. Chain-length-dependent fragmentation patterns were observed, which could aid in predicting the structures of related compounds. This research highlights the challenges of balancing informative low-intensity peaks with accurate spectral matching in databases. Based on our results, combining mass spectrometry with separation techniques, such as liquid chromatography, could enhance structural elucidation for unknown compounds. This study contributes to the broader field of mass spectrometry and structural chemistry, particularly in the analysis of amide compounds, and future directions are proposed for developing robust algorithms for selecting and interpreting low-intensity peaks to improve compound identification in complex mixtures.

Indexed as

amidoamine oxidechain-length dependence of fragmentationstructural elucidation

Identifiers

PMID39654854
PMCPMC11626507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.